A股五张图：狂撒欢乐豆

Market Overview - The AI hardware sector showed collective strength, with liquid cooling servers and PCB stocks experiencing significant gains, while the overall market saw mixed results with the Shanghai Composite Index and ChiNext Index down by 0.01% and 0.29% respectively, and the Shenzhen Component Index up by 0.19% [3][4] PCB Sector - The PCB sector was notably strong, with a 3.41% increase, highlighted by stocks such as Huadian Technology and Shenghong Technology reaching their daily limit up [7][8] - Huadian Technology saw a trading volume exceeding 10 billion, ranking among the top ten in the market, while Shenghong Technology surged nearly 10% in a single day, with a trading volume of approximately 25 billion [8] - The surge in Shenghong Technology's stock price is attributed to reports that NVIDIA will act as a cornerstone investor in its upcoming Hong Kong IPO, following its participation in NVIDIA's supply chain conference [8] Liquid Cooling Sector - The liquid cooling sector experienced a significant rise, with a final increase of 3.59%, driven by stocks like Jialitu and Chuanrun shares hitting their daily limit up [11] - The catalyst for this surge was NVIDIA's announcement of its Q4 fiscal year 2026 earnings, which exceeded Wall Street expectations, and the introduction of its fully liquid-cooled Vera Rubin computing system [11][12] Horse Racing Industry - Reports emerged about Guangzhou planning a 10 square kilometer horse racing industry cooperation zone, with the Hong Kong Jockey Club announcing international standard horse racing events in October [15] - However, the market reaction was muted, as the events will not include betting, leading to a lack of investor interest [15] Changchun High-tech - Changchun High-tech gained attention after its subsidiary, Gensci, received approval for a clinical trial of a drug aimed at treating specific pediatric conditions, leading to a surge in its stock price [17][21] - The stock's performance was influenced by media coverage, which highlighted the drug's potential, despite previous announcements having little impact on the market [18][20]